# Sutro Biopharma, Inc. (STRO)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001382101 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001382101))
- Full page: https://inspectstocks.com/stocks/stro
- Data as of: price 2026-09-28; newest filing used 2026-08-12; latest fiscal period ended 2026-06-30

## Grade

**F** on the balance-sheet rubric used for lenders, 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$180.6M |  |
| Earnings growing overall | failed | -$180.6M | -$142.7M |
| Earnings growing recently | passed | -$180.6M | -$191.1M |
| Earns well on its assets | failed | -92.9% |  |
| Book value per share growing | failed | -$15.59 | $0.43 |

Business quality (the + / − mark): 2 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -395.2% |  |
| Healthy profit margin | failed | -395.2% |  |
| Strong operating margin | failed | -319.6% |  |
| Good return on equity | passed | 136.4% |  |
| Debt under control | passed | -0.12 |  |
| Turns sales into cash | failed | -131.4% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $45.7M |
| Net income, trailing twelve months | -$180.6M |
| Net margin | -395.2% |
| Operating margin | -319.6% |
| Return on equity | 136.4% |
| Debt to equity | -0.12 |
| Diluted EPS, trailing twelve months | -$26.12 |
| Share price | $16.03 |
| Market value | $265.8M |
| Price / sales | 5.8x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/stro)
- [Financial statements](https://inspectstocks.com/stocks/stro/financials)
- [Competitors](https://inspectstocks.com/stocks/stro/peers)
- [Earnings](https://inspectstocks.com/stocks/stro/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.